Aratana

PETX NASDAQ
4.920
-0.010
-0.20%
已退市 09:30 07/22 EDT
开盘
4.930
昨收
4.930
最高
5.01
最低
4.880
成交量
896.68万
成交均量(3M)
134.49万
52周最高
7.16
52周最低
3.300
换手率
18.30%
市值
2.41亿
分时
5日
1月
3月
1年
5年

相关股票

微牛行情栏目提供Aratana PETX股票价格,Aratana股票实时行情,公司简介,财报信息,股本结构等,掌握美港股行情走势,开盘价,收盘价,总市值,换手率,市盈率,收益率等数据,及时把握美股港股投资机会。

公司介绍

Aratana Therapeutics, Inc. is a pet therapeutics company focused on licensing, developing and commercializing of biopharmaceutical products for companion animals. The Company's portfolio includes therapeutic candidates in development consisting of small molecule pharmaceuticals and large molecule biologics that target medical conditions in pets. Its lead product candidates in development include small molecules directed at treating osteoarthritis pain and inflammation (AT-001 for dogs, also known as grapiprant for dogs or GALLIPRANT), appetite stimulation (AT-002 for dogs, also known as capromorelin for dogs or ENTYCE) and post-operative pain (AT-003 for dogs, also known as bupivacaine liposome injectable suspension for dogs or NOCITA). AT-001 is a selective antagonist of the prostaglandin E2 (PGE 2) EP4 receptor (EP4 prostaglandin receptor antagonist or EP4 PRA). AT-002 is a potent and selective ghrelin agonist. Its product candidates also include AT-014, AT-016 and AT-018 for dogs.
展开 >

最近浏览

名称
价格
涨跌幅